


Synthesis and Hydrolysis of 3-Methyladenosine

By TOHRU SAITO and Tozo FUJII*

(Faculty of Pharmaceutical Sciences, Kanazawa University, Takara-machi, Kanazawa 920, Japan)

Summary Methylation of *N'*-benzyloxy-5-formamido-1- β -D-ribofuranosylimidazole-4-carboxamide (1) followed by hydrogenolysis of the *N'*-benzyloxy group and cyclization gave the hitherto unknown 3-methyladenosine (4), which was easily hydrolysed to 3-methyladenine (6) in 0.1 N aq. HCl and to the imidazole ribosides (3) and (5) under basic conditions.





(1) R = H
(2) R = Me

3-SUBSTITUTED adenosines are among the four possible *N*-monosubstituted adenosine isomers, and they have been prepared as modified cyclonucleoside derivatives with¹ or without^{2,3} extra *N*⁶-substituents. Although 3-methyladenosine (4) is the simplest member in this series, it still remains to be synthesized whereas the other three *N*-methyladenosines⁴ are already known. We now report the first synthesis of (4), which represents an extension of our recent general method⁵ for the synthesis of 3,9-dialkyladenines to the nucleoside series.

Treatment of the formamidoimidazole (1),⁶ the readily isolable intermediate in the Dimroth rearrangement of 1-benzyloxyadenosine,⁷ with MeI in HCONMe₂ in the presence of anhydrous K₂CO₃ at room temperature for 9 h furnished the *N*-methylformamido derivative (2), † m.p. 160–161 °C, in 86% yield. Removal of the *N'*-benzyloxy group from (2) was then effected by hydrogenolysis using Raney Ni and H₂ (1 atm, room temp., 70 min) in H₂O in the presence of 1 mol equiv. of toluene-*p*-sulphonic acid (TsOH), and the crude (3)·TsOH that resulted was treated with a little Et₃N in MeOH at room temperature for 48 h, giving the desired compound (4)·TsOH [53% yield from (2)], m.p. ca. 150 °C (decomp.); λ_{\max} (95% EtOH) 272 nm (ϵ 16,500); λ_{\max} (H₂O) (pH 1) unstable; λ_{\max} (H₂O) (pH 7) 270 nm (ϵ 17,400); λ_{\max} (H₂O) (pH 13) unstable; δ [(CD₃)₂SO] 2.28 (3H, s, CMe), 4.19 (3H, s, NMe), 8.59 and 8.74 (1H each, s, purine protons), and 9.12 and 9.21 (2H, =NH₂⁺ or 2 × NH).

As in the case of 3,9-dialkyladenine salts,⁵ (4)·TsOH was found to be unstable under basic conditions: treatment of its aqueous solution with Amberlite CG-400 (OH⁻) at room temperature resulted in the ring opening of the purine unit, and the methylaminoimidazole (5) was isolated in the form of (5)·2HCl·H₂O (87% yield), m.p. 99–102 °C (decomp.). In 0.1 M aq. NaHCO₃ (pH 8.32) at 25 °C, 3-methyladenosine (4) equilibrated with (3), and the pseudo-first-order rate constants and equilibrium constant for the ring opening and cyclization were determined to be $k = 6.6 \times 10^{-3} \text{ min}^{-1}$, $k' = 6.9 \times 10^{-3} \text{ min}^{-1}$, and $K = k/k' = 0.96$.



Rib = β -D-ribofuranosyl

In contrast to the inertness of 3,9-dialkyladenine salts in aqueous acidic solution, (4)·TsOH underwent hydrolysis to afford 3-methyladenine (6)⁸ (92% yield) on treatment with 0.1 N aq. HCl at room temperature for 1 h. For the hydrolysis [(4)·TsOH \rightarrow (6)] at pH 1 and 25 °C a rate constant of $4.0 \times 10^{-2} \text{ min}^{-1}$ and a half life of 17 min were obtained. Adenosine itself was completely stable under similar conditions, and Venner⁹ reported that the rate constant for its hydrolysis at pH 1 and 37 °C was $2.16 \times 10^{-5} \text{ min}^{-1}$. Interestingly, the introduction of the methyl group into adenosine at the 3-position thus made the glycosidic bond cleavage some thousand times easier under acidic conditions.

We acknowledge support of this work by a Grant-in-Aid for Special Project Research from the Ministry of Education, Science and Culture, Japan.

(Received, 16th October 1978; Com. 1116.)

† Satisfactory microanalytical and/or spectroscopic data have been obtained for all new compounds described.

¹ B. R. Baker and J. P. Joseph, *J. Amer. Chem. Soc.*, 1955, **77**, 15.

² V. M. Clark, A. R. Todd, and J. Zussman, *J. Chem. Soc.*, 1951, 2952.

³ J. A. Wright, N. F. Taylor, and J. J. Fox, *J. Org. Chem.*, 1969, **34**, 2632.

⁴ J. W. Jones and R. K. Robins, *J. Amer. Chem. Soc.*, 1963, **85**, 193; T. Fujii, F. Tanaka, K. Mohri, T. Itaya, and T. Saito, *Tetrahedron Letters*, 1973, 4873; B. Singer, L. Sun, and H. Fraenkel-Conrat, *Biochemistry*, 1974, **13**, 1913.

⁵ T. Fujii, T. Saito, and M. Kawanishi, *Tetrahedron Letters*, 1978, 5007.

⁶ T. Fujii, C. C. Wu, T. Itaya, S. Moro, and T. Saito, *Chem. and Pharm. Bull. (Japan)*, 1973, **21**, 1676.

⁷ T. Fujii, C. C. Wu, and T. Itaya, *Chem. and Pharm. Bull. (Japan)*, 1971, **19**, 1368.

⁸ J. W. Jones and R. K. Robins, *J. Amer. Chem. Soc.*, 1962, **84**, 1914.

⁹ H. Venner, *Z. physiol. Chem.*, 1964, **339**, 14.